Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.96
Price to sales ratio
229.62

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3014
PACB
Pacific Biosciences of California, Inc. - Common Stock
1.40 USD-9.68%+3.70%-0.71%+7.69%435.16 M USD
3088
OFIX
Orthofix Medical Inc. - Common Stock
9.70 USD+0.73%-3.29%-18.96%-39.26%395.11 M USD
3224
VMD
Viemed Healthcare, Inc. - Common Shares
8.82 USD-2.11%-2.54%-24.10%+20.33%335.94 M USD
3264
RCEL
Avita Medical, Inc. - Common Stock
10.35 USD+0.29%+2.58%+134.16%+138.48%320.09 M USD

Frequently asked questions about Perspective Therapeutics, Inc.

What is the Perspective Therapeutics, Inc. stock price today?

The current price of Perspective Therapeutics, Inc. (CATX) is 3.09. Over the past 24 hours, the stock has changed by -2.52%. Follow the CATX chart for real-time price dynamics.

What is the stock ticker of Perspective Therapeutics, Inc.?

Perspective Therapeutics, Inc. trades under the ticker CATX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Perspective Therapeutics, Inc. stock going up?

CATX has changed by -7.49% over the last week, +7.67% over the last month, and -8.58% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Perspective Therapeutics, Inc.?

Perspective Therapeutics, Inc. currently has a market capitalization of 352.73 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Perspective Therapeutics, Inc. earnings last quarter?

Last quarter, Perspective Therapeutics, Inc. reported earnings of -0.22 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Perspective Therapeutics, Inc. revenue for the last quarter?

Perspective Therapeutics, Inc. reported quarterly revenue of 81 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Perspective Therapeutics, Inc. net income for the last quarter?

Perspective Therapeutics, Inc. reported net income of -26.79 M for the last quarter. The previous quarter showed -26.19 M, which means net income changed by -2.28%.

How many employees does Perspective Therapeutics, Inc. have?

As of the latest available data, Perspective Therapeutics, Inc. has 166 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Perspective Therapeutics, Inc. stock?

You can buy Perspective Therapeutics, Inc. (CATX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Perspective Therapeutics, Inc. stock?

Investing in Perspective Therapeutics, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CATX chart and related analysis on metatrader.com as part of your research.

Perspective Therapeutics, Inc. Common Stock

Isoray Inc. is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is a registered manufacturer with the FDA and holds multiple 510 clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu. The company went public in 2005. Isoray’s corporate headquarters is located at 350 Hills Street, Suite 106, Richland WA 99354.

News